POSSIBILITIES OF FORECASTING COMPLICATIONS IN PATIENTS WITH METABOLIC SYNDROME

Authors:

Abstract:

In the period from 2013 to 2016, 364 patients aged 20 to 80 years (200 men and 164 women) with newly diagnosed metabolic syndrome were prospectively examined. In patients aged 20–60 years and in the age group 61–80 years, the analysis of the results of the examination of patients with metabolic syndrome allowed us to build a number of regression models that allow predicting variants of metabolic syndrome: diabetic, hypertensive or combined. A study of the incidence of complications of metabolic syndrome showed that in the age group of 20–40 years the incidence of myocardial infarction was 1.9 % and that of ischemic stroke in 0.96 %, in the age group 41–60 years, respectively, 14.5 and 7.6 %; In the group of patients older than 60 years – myocardial infarction was observed in 12.9 % of patients, ischemic stroke in 6.7 % of cases. The analysis of the results of the examination of patients with metabolic syndrome allowed us to build a number of regression models that allow predicting variants of the metabolic syndrome. It has been shown that metabolic syndrome is a factor predisposing to atrial fibrillation and a favourable background for the implementation of risk factors for atrial fibrillation.

Keywords:

metabolic syndrome complications regression analysis prognostic parameters

References:

1. Bochkov VV, Plehanov AN, Cydenova CB. Hronicheskiy nespecificheskiy endometrit: epidemiologija, jetiologiya, patogenez, faktory riska, diagnostika. Vestnik Buryatskogo gosudarstvennogo universiteta. Meditsina i farmatsiya.2015; 2:30–38 [in Russian]
2. Gerilovich AT, Bazina MI, Maisenko DA. Otsenka sostoyaniya zdorovya zhenshhin, ispolzuyushchikh programmy vspomogatelnykh reproduktivnykh tehnologiy. Zaporozhskiy Meditsinskiy Zhurnal. 2014; 4(85);63–66 [in Russian]
3. Dedov II, Shestakova MV, Vikulova OK. Saharnyj diabet v Rossiyskoy Federatsii: rasprostranennost, zabolevaemost, smertnost, parametry uglevodnogo obmena i struktura saharosnizhayushchey terapii po dannym Federalnogo registra saharnogo diabeta, status 2017 g. Saharnyj diabet. 2018; 21(3):144–159. https://doi.org/10.14341/DM9686 [in Russian]
4. Dolgih JuA, Verbovoy AF, Mitroshina EV. Otsenka gormonalno–metabolicheskih pokazatelej i sostoyaniya serdechno–sosudistoy sistemy pri ozhirenii, manifestirovavshem v pubertatnyi period u junoshey . Spravochnik vracha obshchey praktiki. 2013;1:041–049. [in Russian]
5. Koval SN, Bozhko VV, Snegurskaja IA. Sovremennye predstavleniya o vozmozhnosti prognozirovaniya techeniya arterialnoy gipertenzii pri metabolicheskom sindrome . Arterialnaya gipertenziya.2012; 6 (26):34–39. [in Russian]
6. Benrick A, Chanclón B, Micallef P. Adiponectin protects against development of metabolic disturbances in a PCOS mouse model. Proc Natl Acad Sci USA. 2017; 114(34):E7187–E7196. https://doi.org/10.1073/pnas.1708854114
7. Cobbold C. Type 2 diabetes mellitus risk and exercise: is resistin involved? J Sports Med Phys Fitness. 2019; 59(2):290–297. https://doi.org/10.23736/S0022–4707.18.08258–0
8. Derosa G, Catena G, Gaudio G. Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dIabeteS in obese patients (The resistin trial). Cytokine. 2020; 127:154947. https://doi.org/10.1016/j.cyto.2019.154947
9. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014; 13:103. https://doi.org/10.1186/1475–2840–13–103
10. Libis RA, Isaeva EN. The possibility of using the index of visceral obesity in diagnosing the metabolic syndrome and predicting the risk of its complications. Russian Cardiology Journal. 2014; 9 (113):48–53.
11. Park HK, Kwak MK, Kim HJ, Ahima RS. Linking resistin, inflammation, and cardiometabolic diseases. Korean J Intern Med. 2017; 32(2):239–247. https://doi.org/10.3904/kjim.2016.229
12. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens.Rep.2018; 20(2):12. https://doi.org/10.1007/s11906–018–0812–z

Publication:

«World of Medicine and Biology» Vol. 17 No. 78 (2021) , с. 120-125
УДК 616–008

DOI:

https://doi.org/10.26724/2079-8334-2021-4-78-120-125